Restatement of Previously Issued Financial Statements (Details 3) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Balance, amount			$ 15,365,315	$ 18,028,229
Common shares issued on exercise of warrants, amount			0
Reverse merger adjustment, amount			4,396,034
Common shares issued on conversion of debt, amount			6,516,056
Common shares issued on conversion of Series H preferred stock, amount			0
Common shares issued on conversion of Series C preferred stock, Amount			0
Common shares issued on true-up of Series C preferred stock, Amount			4,257,969
Foreign currency translation adjustment			121,495	(306,835)
Net loss	$ (7,877,343)	$ (10,860,687)	(10,785,683)	(14,695,711)
Balance, Amount	11,079,118	$ 17,968,724	11,079,118	$ 17,968,724
Additional Paid-In Capital
Balance, amount			127,757,269
Common shares issued on exercise of warrants, amount			(3,849)
Reverse merger adjustment, amount			(4,428,916)
Common shares issued on conversion of debt, amount			6,506,430
Common shares issued on conversion of Series H preferred stock, amount			(3,331)
Common shares issued on conversion of Series C preferred stock, Amount			(1,094)
Common shares issued on true-up of Series C preferred stock, Amount			4,246,069
Balance, Amount	134,072,578		134,072,578
Accumulated Deficit
Balance, amount			(122,187,673)
Common shares issued on exercise of warrants, amount			0
Reverse merger adjustment, amount			0
Common shares issued on conversion of debt, amount			0
Common shares issued on conversion of Series H preferred stock, amount			0
Common shares issued on conversion of Series C preferred stock, Amount			0
Common shares issued on true-up of Series C preferred stock, Amount			0
Foreign currency translation adjustment			0
Net loss			(10,719,328)
Balance, Amount	(132,907,001)		(132,907,001)
Additional Paid In Capital As Previously Reported
Balance, amount			127,757,269
Common shares issued on exercise of warrants, amount			(3,849)
Reverse merger adjustment, amount			28,167,903
Common shares issued on conversion of debt, amount			6,506,430
Common shares issued on conversion of Series H preferred stock, amount			(3,331)
Common shares issued on conversion of Series C preferred stock, Amount			(1,094)
Common shares issued on true-up of Series C preferred stock, Amount			4,246,069
Foreign currency translation adjustment			0
Net loss			0
Balance, Amount	166,669,397		166,669,397
Additional Paid In Capital Adjustments
Balance, amount			0
Common shares issued on exercise of warrants, amount			0
Reverse merger adjustment, amount			(32,596,819)
Common shares issued on conversion of debt, amount			0
Common shares issued on conversion of Series H preferred stock, amount			0
Common shares issued on conversion of Series C preferred stock, Amount			0
Common shares issued on true-up of Series C preferred stock, Amount			0
Foreign currency translation adjustment			0
Net loss			0
Balance, Amount	(32,596,819)		(32,596,819)
Accumulated Deficit As Previously Reported
Balance, amount			(122,187,673)
Common shares issued on exercise of warrants, amount			0
Reverse merger adjustment, amount			0
Common shares issued on conversion of debt, amount			0
Common shares issued on conversion of Series H preferred stock, amount			0
Common shares issued on conversion of Series C preferred stock, Amount			0
Common shares issued on true-up of Series C preferred stock, Amount			0
Foreign currency translation adjustment			0
Net loss			(25,206,073)
Balance, Amount	(147,393,746)		(147,393,746)
Accumulated Deficit Adjustments
Balance, amount			0
Common shares issued on exercise of warrants, amount			0
Reverse merger adjustment, amount			0
Common shares issued on conversion of debt, amount			0
Common shares issued on conversion of Series H preferred stock, amount			0
Common shares issued on conversion of Series C preferred stock, Amount			0
Common shares issued on true-up of Series C preferred stock, Amount			0
Foreign currency translation adjustment			0
Net loss			14,486,745
Balance, Amount	$ 14,486,745		$ 14,486,745